Clinical Trial

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Name: Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease — clinical trial record (NCT06056921)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Record status

This record was last updated September 28, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Summary

This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease

Trial Details

NCT Number	NCT06056921
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Enrollment	24 participants
Start Date	2023-08-31
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-08-31 (estimated)
Updated on ClinicalTrials.gov	2023-09-28